Data gathered: December 10
Data Bits
| Data Bits | Value / Change | Benchmark |
|---|---|---|
| Job Posts | N/A | N/A |
| Sentiment | N/A | N/A |
| Webpage traffic | N/A | N/A |
| Employee Rating | N/A | N/A |
| Google Adspend | $ N/A | N/A |
| Google Trends | N/A | N/A |
| Linkedin Employees | N/A | N/A |
| Patents | N/A | N/A |
| 4chan Mentions | N/A | N/A |
| Facebook Engagement | N/A | N/A |
| Facebook followers | N/A | N/A |
| Stocktwits Mentions | N/A | N/A |
| Stocktwits Subscribers | N/A | N/A |
| Twitter Followers | N/A | N/A |
| Youtube Subscribers | N/A | N/A |
| News Mentions | N/A | N/A |
| Reddit Mentions | N/A | N/A |
| Business outlook | N/A | N/A |
In the news
Global Biologics CDMO Market Research Report 2023-2033: Biologics Revolutionizes Treatments, Complex Biologic Molecules Drive Demand for CDMO ServicesDecember 6 - GlobeNewswire |
|
 |
S&P 500 Futures Drop in Premarket Trading; GitLab, Core & Main LeadDecember 4 - MarketWatch |
Antibody Contract Manufacturing Market to Hit US$ 20.85 Billion at 13.1% CAGR by 2034: Fact.MR StudyDecember 4 - GlobeNewswire |
|
 |
Catalent, Inc. (NYSE:CTLT) Short Interest Up 5.9% in NovemberDecember 3 - ETF Daily News |
 |
Exelixis (NASDAQ:EXEL) vs. Genocea Biosciences (NASDAQ:GNCAQ) Critical AnalysisDecember 3 - ETF Daily News |
Contract Pharmaceutical Dose Manufacturing Industry Composition, Size, Market Share and Outlook Report 2023December 1 - GlobeNewswire |
About Catalent
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials.
| Price | $37.27 |
| Target Price | Sign up |
| Market Cap | $6.72B |
| Dividend Yield | 0 |
| Industry | Biotechnology |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
|---|---|---|---|---|---|
| Q1 '23 | 1.04B | 857M | 180M | -227M | -174M |
| Q4 '22 | 1.15B | 762M | 387M | 80M | 219M |
| Q3 '22 | 1.02B | 764M | 251M | -5M | 97M |
| Q2 '22 | 1.12B | 825M | 462M | 168M | 127M |
| Q1 '22 | 1.27B | 850M | 423M | 141M | 276M |
Insider Transactions
| Ryan Michelle R filed to buy 1,979 shares at $50. September 5 '23 |
| GREISCH JOHN J filed to buy 34,000 shares at $50.2. September 1 '23 |
| Pravda Ricardo filed to sell 30,224 shares at $44.5. August 25 '23 |
| Hunt Patricia filed to sell 11,289 shares at $44.8. August 25 '23 |
| Lickfold Charles filed to sell 11,339 shares at $44.7. August 25 '23 |